Chicago – The use of the medication citalopram was associated with a reduction in agitation in patients with Alzheimer disease, although at the dosage used in the study, patients experienced mild cognitive and cardiac adverse effects that might limit the practical application of this medication at the dosage of 30 mg per day, according to a study in the February 19 issue of JAMA.
Agitation, which is common in patients with Alzheimer disease, is persistent, difficult to treat, costly, and associated with severe adverse consequences for patients and caregivers. Pharmacologic therapies have proven inadequate and antipsychotic drugs continue to be widely used for this condition despite serious safety concerns, including increased risk of death, and uncertain efficacy, according to background information in the article. Citalopram, an antidepressant drug frequently used in older individuals, has been proposed as an alternative to antipsychotic drugs for agitation and aggression in dementia, yet there is limited evidence for its efficacy and safety.
An increased risk for Alzheimer disease (AD) appears to be associated with elevated blood levels of a byproduct of the pesticide DDT, which was banned in the United States in 1972 but is still used for agriculture in other countries, according to a study by Jason R. Richardson, Ph.D., of the Rutgers Robert Wood Johnson Medical School and Environmental and Occupational Health Sciences Institute, Piscataway, N.J., and colleagues.
AD is the most common neurodegenerative disease in the world and the number of cases is expected to increase. Risk factors for late-onset AD (after age 60 years) are not completely understood but include environmental and lifestyle factors. Having a version of a gene, an apolipoprotein E 4 (APOE 4 ) allele, also appears to increase risk, according to the study background. Read more…
In case of neurodegenerative diseases such as Alzheimer’s disease (AD), you may start your work from the study of synapses – gaps between the nerve ends – as synaptic dysfunctions are considered as most important disorders in these diseases.
Although a great deal of work has been done on neurodegenerative diseases but they still lack fully potential “disease-modifying therapies”. Disease-modifying therapy (cures the disease as opposed to the cure of only symptoms in symptomatic treatment) may start from ‘toxin-reducing’ approach.
One of the reasons of the lack of better disease-modifying drugs is incomplete understanding of mechanisms underlying the neurodegenerative diseases. Several mechanisms/pathways have been proposed such as “accumulation of neurotoxic substances, inflammation, lipid metabolism, oxidative stress, autophagy, protein degradation and mitochondrial dysfunction” but no drug is still pointing to all these mechanisms.
For the development of potential drugs against AD, better animal models have to be developed. Not only animal models but also significant biomarkers are not present for identification of AD. Presence of biomarkers could help us to understand that how early we have to start the treatment of AD. Read more…
Alzheimer’s disease is a degenerative disorder that affects the brain and causes dementia, especially late in life. “According to the 2010 World Alzheimer report, there are an estimated 35.6 million people worldwide living with dementia at a total cost of over US$600 billion in 2010, and the incidence of AD throughout the world is expected to double in the next 20 years,” Researchers reported.
There is no known treatment to slow down the progression of this disease.
Finding the biomarkers for the progress of the disease is one of the potential targets of researchers. Biomarkers were a kind of “biological tools that ‘mark’ the presence of pathology, for the early diagnosis of AD and for measuring clinical drug trial outcomes.” Read more…
Researchers have found that the people, who develop skin cancer, may have less chances of developing Alzheimer’s disease in the older ages. Read more…